Mabion SA MAB

FDA grants Type B pre-IND meeting, enabling critical alignment with the Agency on the development strategy for RTX-NPOddifact and Mabion aim to bring rituximab's well-established activity in ITP to formal FDA approval for the first time Paris, France – August 26, 2026 — Oddifact SAS, a French rare disease TechDev company, and Mabion S.A. (WSE: MAB), a Polish biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has granted a Type B pre-IND meeting for RTX-NP (Ma